Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva and Gemcitabine in Metastatic Breast Cancer
NCT00059852Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2003
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in breast cancer, sponsored by Cancer and Leukemia Group B. Primary endpoint: Response Rate up to 5 years. Started Jun 2003; status: completed.
02
Drugs
erlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00059852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00059852.